General Updates

AZERBAIJAN ONCOLOGY MARKET – REGULATORY & COMMERCIALISATION UPDATE Beta Drugs has achieved an important regulatory milestone in Azerbaijan, receiving approvals for its oncology portfolio across multiple dosage forms, including: * Liquid injectables * Lyophilised injectables * Tablets and capsules * Oral suspensions The Company has already filed 15 oncology product dossiers for registration in Azerbaijan. A further 15 oncology products are expected to be ready for filing within the next month, significantly expanding the Company’s oncology portfolio in the market. With this portfolio, Beta Drugs expects to be one of a few oncology players present in the Azerbaijan market, providing an opportunity to establish a meaningful presence across multiple oncology therapies and dosage forms. The Company is actively working towards commercialisation and securing initial oncology business from Azerbaijan during the current financial year. The Azerbaijan expansion is an important step in Beta Drugs’ strategy to build its international oncology franchise and expand its presence across emerging global markets.